Hexobarbital

Hexobarbital

Clinical data
ATC code	N01AF02 (WHO) N05CA16 (WHO)
Pharmacokinetic data
Protein binding	25%
Identifiers
IUPAC name 5-(1-cyclohexenyl)- 1,5-dimethyl- hexahydropyrimidine- 2,4,6-trione
CAS Number	56-29-1
PubChem CID	3608
DrugBank	EXPT03301
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C12H16N2O3
Molar mass	236.267 g/mol

WikiDoc Resources for Hexobarbital
Articles
Most recent articles on Hexobarbital Most cited articles on Hexobarbital Review articles on Hexobarbital Articles on Hexobarbital in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Hexobarbital Images of Hexobarbital Photos of Hexobarbital Podcasts & MP3s on Hexobarbital Videos on Hexobarbital
Evidence Based Medicine
Cochrane Collaboration on Hexobarbital Bandolier on Hexobarbital TRIP on Hexobarbital
Clinical Trials
Ongoing Trials on Hexobarbital at Clinical Trials.gov Trial results on Hexobarbital Clinical Trials on Hexobarbital at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Hexobarbital NICE Guidance on Hexobarbital NHS PRODIGY Guidance FDA on Hexobarbital CDC on Hexobarbital
Books
Books on Hexobarbital
News
Hexobarbital in the news Be alerted to news on Hexobarbital News trends on Hexobarbital
Commentary
Blogs on Hexobarbital
Definitions
Definitions of Hexobarbital
Patient Resources / Community
Patient resources on Hexobarbital Discussion groups on Hexobarbital Patient Handouts on Hexobarbital Directions to Hospitals Treating Hexobarbital Risk calculators and risk factors for Hexobarbital
Healthcare Provider Resources
Symptoms of Hexobarbital Causes & Risk Factors for Hexobarbital Diagnostic studies for Hexobarbital Treatment of Hexobarbital
Continuing Medical Education (CME)
CME Programs on Hexobarbital
International
Hexobarbital en Espanol Hexobarbital en Francais
Business
Hexobarbital in the Marketplace Patents on Hexobarbital
Experimental / Informatics
List of terms related to Hexobarbital

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Hexobarbital is a barbiturate derivative having hypnotic and sedative effects. It was used in the 1940s-1950s as an agent for inducing anesthesia for surgery and has a relatively fast onset of effects and short duration of action. However it can be difficult to control the depth of anesthesia with hexobarbital which makes it quite dangerous, and it has now been replaced by safer drugs in human medicine, usually thiopental would be the barbiturate of choice for this application these days. Hexobarbital was also marketed as a rapid-acting sleeping pill with short duration (tradenames: Citopan, Evipan and others, usually in 250 mg strength tablets). Hexobarbital is still used in some scientific research.

Further reading

• Takenoshita R, Toki S (2004). "[New aspects of hexobarbital metabolism: stereoselective metabolism, new metabolic pathway via GSH conjugation, and 3-hydroxyhexobarbital dehydrogenases]". Yakugaku Zasshi. 124 (12): 857–71. PMID 15577260.
• Wahlström G (1998). "A study of the duration of acute tolerance induced with hexobarbital in male rats". Pharmacol Biochem Behav. 59 (4): 945–8. PMID 9586853.
• Korkmaz S, Ljungblad E, Wahlström G (1995). "Interaction between flumazenil and the anesthetic effects of hexobarbital in the rat". Brain Res. 676 (2): 371–7. PMID 7614008.CS1 maint: Multiple names: authors list (link)
• Dall V, Orntoft U, Schmidt A, Nordholm L (1993). "Interaction of the competitive AMPA receptor antagonist NBQX with hexobarbital". Pharmacol Biochem Behav. 46 (1): 73–6. PMID 8255925.CS1 maint: Multiple names: authors list (link)